Latest Continuous Disclosure News

Greatland Resources has downgraded its FY26 gold production target and significantly increased capital expenditure forecasts for its Telfer Project, prompting a sharp share price reaction and detailed ASX disclosure.

Elanor Commercial Property Fund has received an unsolicited off-market takeover offer from the Lederer Group, prompting the formation of an Independent Board Committee to evaluate the proposal and advise securityholders.

Trigg Minerals has disclosed a significant acquisition of the Tennessee Mountain tungsten project in Nevada, explaining recent unusual trading activity in its shares. The company confirms compliance with ASX disclosure rules and plans a full announcement before market open on August 7, 2025.

SRJ Technologies clarifies its financial position and strategic rationale behind a recent capital raise and acquisition of a UAE entity, addressing ASX concerns over its viability and voluntary suspension.

SportsHero Limited has responded to ASX queries about recent unusual trading activity, confirming no undisclosed price-sensitive information and ongoing compliance with disclosure rules.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.

Orcoda Limited has clarified the materiality and timing of disclosures related to its ACTA trial and new SaaS contracts, confirming compliance with ASX Listing Rules and explaining the rationale behind its announcements.

Boss Energy has acknowledged significant upward revisions to operating and capital costs at its Honeymoon Uranium Project, alongside challenges in achieving production targets, prompting an independent review.

Leeuwin Metals Ltd has addressed a sudden spike in its share price and trading volume, confirming no undisclosed material information exists and attributing the movement to external market factors and a new research report.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.